Oklahoma Healthcare Wire: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Oklahoma Healthcare Wire.

Press releases published on March 2, 2026

Mar. 2, 2026

ADMA Biologics Announces $125 Million Accelerated Share Repurchase with JPMorgan as Part of a Planned $200 Million 2026 Total Share Repurchase Initiative

Indeterminate GlobeNewswire

Mar. 2, 2026

NRx Pharmaceuticals (Nasdaq: NRXP) Appoints Prof. Joshua Brown MD, PhD, as Chief Medical Innovation Officer

Indeterminate GlobeNewswire

Mar. 2, 2026

Agios’ PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in the United Arab Emirates

Indeterminate GlobeNewswire

Mar. 2, 2026

uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease

Indeterminate GlobeNewswire

Mar. 2, 2026

Intuitive Expands Investment and Footprint in Europe

Indeterminate GlobeNewswire

Mar. 2, 2026

Deucrictibant Data Supporting Potentially Differentiated Profile for the On-Demand and Prophylactic Treatment of Bradykinin-Mediated Angioedema Presented at AAAAI 2026

Indeterminate GlobeNewswire

Mar. 2, 2026

Alaunos Therapeutics Announces Positive Preclinical Proof-of-Concept Data for ALN1003, a Differentiated Non-Hormonal Oral Treatment for Obesity and Related Metabolic Disorders

Indeterminate GlobeNewswire

Mar. 2, 2026

Royalty Pharma and Zymeworks Enter Into $250 Million Royalty-Backed Note Financing

Indeterminate GlobeNewswire

Mar. 2, 2026

Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing

Indeterminate GlobeNewswire

Mar. 2, 2026

RadNet Reports Fourth Quarter 2025 Results, Including Record Revenue and Adjusted EBITDA⁽¹⁾ and Releases 2026 Financial Guidance

Indeterminate GlobeNewswire

Mar. 2, 2026

Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Indeterminate GlobeNewswire

Mar. 2, 2026

Belite Bio Reports Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update

Indeterminate GlobeNewswire

Mar. 2, 2026

RadNet Acquires Gleamer, Making RadNet’s DeepHealth the Largest Provider of Radiology Clinical AI Solutions Worldwide

Indeterminate GlobeNewswire

Mar. 2, 2026

Egle Therapeutics and Consortium Partners Awarded €8 Million Grant from Horizon Europe to Advance Clinical Development of EGL-001 in Neoadjuvant Head and Neck Cancer

Indeterminate GlobeNewswire

Mar. 2, 2026

Press Release: Sanofi’s rilzabrutinib earns orphan drug designation in Japan for IgG4-related disease

Indeterminate GlobeNewswire

Mar. 2, 2026

VERAXA Biotech Shareholders Approve Merger and Issuance of New Shares to Voyager Acquisition Corp.

Indeterminate GlobeNewswire

Mar. 2, 2026

Communiqué de presse : Le rilzabrutinib de Sanofi obtient la désignation de médicament orphelin au Japon pour la maladie liée aux IgG4

Indeterminate GlobeNewswire

Mar. 2, 2026

InnoCare’s next-generation TRKi Zurletrectinib Receives Priority Review for the Treatment of Pediatric Patients with Solid Tumors in China

Indeterminate GlobeNewswire